Cingulate publishes PK data for ADHD drug CTx-1301 in CNS Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
August 11, 2026 8:30 AM EDTKANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release (PTR) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs. The open-access manuscript provides clinicians and researchers with pharmacokinetic data supporting CTx-1301 (dexmethylphenidate HCl), Cingulate's lead product candidate for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Available through open access, the manuscript expands Cingulate's growing body of peer-reviewed evidence supporting CTx-1301 and follows the... More
